Biotech venture trending downward 

Venture financing faltered (but just a touch) last year compared with 2018, according to a new report from Evaluate. Some $13.9 billion was poured into biopharma in 2019 — compared with $17.9 billion the previous year. 

That seems like a big difference, but private investors were concerned in 2018 about the long-term implications of such a massive amount of capital. So 2019 marked a year of restraint in investment, Evaluate notes. 

Biopharmas could be in for a bit of a rollercoaster this year, the analysts predict. Drug pricing rhetoric will likely escalate as the election looms, which could mean a volatile stock market — which might lead to even more prudence among biopharma venture investors.